MAGNIFY

The Next Generation Incubator at CNSI

Sixal is a pre-clinical company with a monoclonal antibody prophylactic therapeutic for IgE-mediated disorders including food allergies (FA), asthma, urticaria and mastocytosis.

Market:

In the U.S., someone is admitted to the ER every 20 minutes with anaphylaxis due to food allergy. Food allergies affect 15 million in the U.S. and 19 million in the EU. Currently, there are NO APPROVED prophylactic treatments for food allergies today. Validated target reduces potential for off-target toxicity. Superior safety profile from in vitro and ex vivo testing. Rapid therapeutic effect onset, likely at lower dosing, will address a larger patient population than other approaches.

Technology:

Low Affinity anti-IgE transiently binds to and releases from surface-bound IgE on Mast Cells and Basophil (allergic effector cells), causing internalization of cell receptors rendering them unavailable for allergen-binding and simultaneously reducing stored inflammatory mediators via piecemeal degranulation.

Advantages:

  • Validated targeting reduces off-target toxicity
  • Superior safety profile
  • Rapid therapeutic onset

Development Stage:

Pre-clinical

Patents Issued:

Sixal has several patents filed in 2013 and 2017. More information available upon request.

Select Publications:

Coming Soon!  

Company Contact:

General contact: Tim Tiemann, TTiemann@sixal.com, 661-514-8710